Global Dermatology Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Dermatology Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Dermatology Partnering 2010-2017: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Dermatology partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Dermatology partnering agreement structure

Dermatology partnering contract documents

Top Dermatology deals by value

Most active Dermatology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dermatology deals.

The report presents financial deal terms values for Dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of dermatology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in dermatology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading dermatology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to dermatology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2010. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope

Global Dermatology Partnering 2010-2017 is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.

Global Dermatology Partnering 2010-2017 includes:

Trends in dermatology dealmaking in the biopharma industry since 2010

Analysis of dermatology deal structure

Access to headline, upfront, milestone and royalty data

Access to over 700 dermatology deal records

The leading dermatology deals by value since 2010

The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

In Global Dermatology Partnering 2010-2017, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Dermatology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 650 dermatology deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Dermatology Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of dental deal trends since 2010

Access dermatology deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between dermatology partner companies

Comprehensive access to over 750 links to actual dermatology deals entered into by the world's biopharma companies

Indepth review of dermatology deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner dermatology opportunities

Uncover companies actively partnering dermatology opportunities

Global Dermatology Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Dermatology dealmaking
2.1. Introduction
2.2. Dermatology partnering over the years
2.3. Dermatology partnering by deal type
2.4. Dermatology partnering by industry sector
2.5. Dermatology partnering by stage of development
2.6. Dermatology partnering by technology type
2.7. Dermatology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Dermatology partnering
3.1. Introduction
3.2. Disclosed financials terms for Dermatology partnering
3.3. Dermatology partnering headline values
3.4. Dermatology deal upfront payments
3.5. Dermatology deal milestone payments
3.6. Dermatology royalty rates

Chapter 4 - Leading Dermatology deals and dealmakers
4.1. Introduction
4.2. Most active in Dermatology partnering
4.3. List of most active dealmakers in Dermatology
4.4. Top Dermatology deals by value

Chapter 5 - Dermatology contract document directory
5.1. Introduction
5.2. Dermatology partnering deals where contract document available

Chapter 6 - Dermatology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Dermatology therapeutic target

Appendices

Appendix 1 - Directory of Dermatology deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Dermatology deals by deal type 2010 to 2017
Appendix 3 - Directory of Dermatology deals by stage of development 2010 to 2017
Appendix 4 - Directory of Dermatology deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Dermatology partnering since 2010
Figure 2: Dermatology partnering by deal type since 2010
Figure 3: Dermatology partnering by industry sector since 2010
Figure 4: Dermatology partnering by stage of development since 2010
Figure 5: Dermatology partnering by technology type since 2010
Figure 6: Dermatology partnering by indication since 2010
Figure 7: Dermatology deals with a headline value
Figure 8: Dermatology deals with upfront payment values
Figure 9: Dermatology deals with milestone payment
Figure 10: Dermatology deals with royalty rates
Figure 11: Active Dermatology dealmaking activity- 2010 to 2017
Figure 12: Top Dermatology deals by value since 2010
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting&hellip
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and&hellip
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries,&hellip
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the&hellip
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The&hellip
  • Skin And Soft Tissue Infections - Pipeline Review, H2 2017
    Published: 25-Jul-2017        Price: US 2000 Onwards        Pages: 40
    Skin And Soft Tissue Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H2 2017, provides an overview of the Skin And Soft Tissue Infections (Dermatology) pipeline landscape. Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues beneath it. Viruses, bacteria, and fungi generally ......
  • Pressure Ulcers - Pipeline Review, H2 2017
    Published: 25-Jul-2017        Price: US 2000 Onwards        Pages: 37
    Pressure Ulcers - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H2 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape. Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body......
  • Global Onychomycosis (Tinea Unguium) Drug Detailed Analysis Report 2017-2022
    Published: 21-Jul-2017        Price: US 3250 Onwards        Pages: 118
    This report splits Onychomycosis (Tinea Unguium) Drug by Product Drug Form, by Product Usage Type. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. And this report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Onychomycosis (Tinea Unguium) Drug industry. ......
  • Global Pressure Ulcer Treatment Products Sales Market Report 2017
    Published: 20-Jul-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Pressure Ulcer Treatment Products market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Pressure Ulcer Treatment Products for these regions, from 2012 to 2022 (forecast), covering - United States - China......
  • Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 225
    Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, j......
  • Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 67
    Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2017, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape. Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ......
  • Warts - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 86
    Warts - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape. Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly......
  • Global Facial Injectables Market Size, Status and Forecast 2022
    Published: 18-Jul-2017        Price: US 3300 Onwards        Pages: 92
    This report studies the global Facial Injectables market, analyzes and researches the Facial Injectables development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Allergan plc - Ipsen - Merz Pharma - Suneva Medical - Medytox - Sinclair Pharma - Bloomage BioTechnology - Anika Therapeutics - Prollenium Medical Technologies ......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Botox Market 2017 Forecast to 2022
    Published: 17-Jul-2017        Price: US 4880 Onwards        Pages: 118
    Botox is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species in the reproduction process. Botox is a polypeptide which molecular weight is 150kD and is also one of the most poisonous natural proteins. It is so easy to be produced, purified and refined due to its stable property that Botox is used widely in Experimental Research and Clinical Application at the early stage.Scope of the Report:This report focuses on the Botox in Global mar......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs